Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.

ABSTRACT:

SUBMITTER: Nanna MG 

PROVIDER: S-EPMC12046440 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature